prikaz prve stranice dokumenta STUDIJA ML20474 PRIMJENE ERITROPOETINA BETA (NEORECORMON) u LIJEČENJU ANEMIJE PREDIJALIZNIH BOLESNIKA – HRVATSKO ISKUSTVO
  Download
PDF 219.17 KB
Scientific paper - Original scientific paper
STUDIJA ML20474 PRIMJENE ERITROPOETINA BETA (NEORECORMON) u LIJEČENJU ANEMIJE PREDIJALIZNIH BOLESNIKA – HRVATSKO ISKUSTVO
Acta medica Croatica : Časopis Akademije medicinskih znanosti Hrvatske, 70 (2017), Suplement 2; 14-18. urn:nbn:hr:184:367067
Prkačin, Ingrid; Klarić, Dragan; Lovčić, Vesna; Galešić, Krešimir; Ilić, Mario; Rački, Sanjin

Cite this document

Prkačin, I., Klarić, D., Lovčić, V., Galešić, K., Ilić, M. & Rački, S. (2017). STUDIJA ML20474 PRIMJENE ERITROPOETINA BETA (NEORECORMON) u LIJEČENJU ANEMIJE PREDIJALIZNIH BOLESNIKA – HRVATSKO ISKUSTVO. Acta medica Croatica : Časopis Akademije medicinskih znanosti Hrvatske, 70. (Suplement 2), 14-18. Retrieved from https://urn.nsk.hr/urn:nbn:hr:184:367067

Prkačin, Ingrid, et al. "STUDIJA ML20474 PRIMJENE ERITROPOETINA BETA (NEORECORMON) u LIJEČENJU ANEMIJE PREDIJALIZNIH BOLESNIKA – HRVATSKO ISKUSTVO." Acta medica Croatica : Časopis Akademije medicinskih znanosti Hrvatske, vol. 70, no. Suplement 2, 2017, pp. 14-18. https://urn.nsk.hr/urn:nbn:hr:184:367067

Prkačin, Ingrid, Dragan Klarić, Vesna Lovčić, Krešimir Galešić, Mario Ilić and Sanjin Rački. "STUDIJA ML20474 PRIMJENE ERITROPOETINA BETA (NEORECORMON) u LIJEČENJU ANEMIJE PREDIJALIZNIH BOLESNIKA – HRVATSKO ISKUSTVO." Acta medica Croatica : Časopis Akademije medicinskih znanosti Hrvatske 70, no. Suplement 2 (2017): 14-18. https://urn.nsk.hr/urn:nbn:hr:184:367067

Prkačin, I., et al. (2017) 'STUDIJA ML20474 PRIMJENE ERITROPOETINA BETA (NEORECORMON) u LIJEČENJU ANEMIJE PREDIJALIZNIH BOLESNIKA – HRVATSKO ISKUSTVO', Acta medica Croatica : Časopis Akademije medicinskih znanosti Hrvatske, 70(Suplement 2), pp. 14-18. Available at: https://urn.nsk.hr/urn:nbn:hr:184:367067 (Accessed 25 April 2024)

Prkačin I, Klarić D, Lovčić V, Galešić K, Ilić M, Rački S. STUDIJA ML20474 PRIMJENE ERITROPOETINA BETA (NEORECORMON) u LIJEČENJU ANEMIJE PREDIJALIZNIH BOLESNIKA – HRVATSKO ISKUSTVO. Acta medica Croatica : Časopis Akademije medicinskih znanosti Hrvatske [Internet]. 2017 April 06 [cited 2024 April 25];70(Suplement 2):14-18. Available at: https://urn.nsk.hr/urn:nbn:hr:184:367067

I. Prkačin, D. Klarić, V. Lovčić, K. Galešić, M. Ilić and S. Rački, "STUDIJA ML20474 PRIMJENE ERITROPOETINA BETA (NEORECORMON) u LIJEČENJU ANEMIJE PREDIJALIZNIH BOLESNIKA – HRVATSKO ISKUSTVO", Acta medica Croatica : Časopis Akademije medicinskih znanosti Hrvatske, vol. 70, no. Suplement 2, pp. 14-18, April 2017. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:367067. [Accessed: 25 April 2024]

Please login to the repository to save this object to your list.
Metadata
Title (croatian)STUDIJA ML20474 PRIMJENE ERITROPOETINA BETA (NEORECORMON) u LIJEČENJU ANEMIJE PREDIJALIZNIH BOLESNIKA – HRVATSKO ISKUSTVO
AuthorIngrid Prkačin
AuthorDragan Klarić
AuthorVesna Lovčić
AuthorKrešimir Galešić
AuthorMario Ilić
AuthorSanjin Rački
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of Internal Medicine)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Abstract (croatian)
Prikazano je prospektivno, neintervencijsko, opservacijsko praćenje učinkovitosti i podnošljivosti eritropoetina beta (NeoRecormon®) u liječenju anemije u bolesnika s kroničnom bubrežnom bolesti (KBB) koji još nisu podvrgnuti nadomjestnom bubrežnom liječenju u Hrvatskoj. U studiji ML20474 uključeno je ukupno 368 bolesnika u 3 do 5. stadiju KBB s anemijom u kojih je bilo indicirana primjena lijekova koji stimuliraju eritropoezu (LSE). Svi su bolesnici primili eritropoetin beta (Neorecormon) supkutano u dozi od 4000 do 6000 IU jednom tjedno u razdoblju do korekcije anemije ili porasta Hb za 10 g/L a potom jednom tjedno u reduciranoj dozi od 50% u odnosu na početnu. Bolesnici su praćeni u razdoblju od 3 do maksimalno 52 mjeseca, prosječno 13.6 (Std.dev.10,36) mjeseci. Većina bolesnika bili su muškarci (55,3%), dob preko 51 godina (81,3%). Medijan vrijednosti razine hemoglobina iznosio je 93.5 g/L na početku studije a nakon 12 mjeseci 104,23 g/L. Nije bilo statistički značajne razlike u razini Hb ovisno o uzroku osnovne bubrežne bolesti i dobi bolesnika. Na kraju praćenja većina je bolesnika navela bolje podnošenje napora, bolje spavanje i manju razdražljivost. Nuspojave primjene terapije eritropoetinom beta nismo uočili. Rezultati pokazuju da je primjena učinkovita i sigurna u liječenju anemije u bolesnika s KBB koji nisu započeli liječenje nadomještanjem bubrežne funkcije.
Abstract (english)
We performed observational multicenter study on CKD patients in stage 3-5, with renal anemia. Key inclusion criteria were: haemoglobin level > 6.0 g/dL, age >18 years and written inform consent. Exclusion criteria were dialysis and transplanted patients and haemoglobin level > 12.0 g/dL. Study was performed from 2006.-2012. and 368 patients were included. All patients received Erythropoietin beta (Neorecormon®; Roche, Basel, Switzerland) subcutaneously in dose of 4000-6000 IU every week during the correction phase of anemia treatment or once weekly 2000-4000IU during the maintenance treatment. Iron supplementation was administrated orally in >80% patients in order to achieve serum ferritin 200-500 μg/L. From 368 patients on beginning, 246 were followed and statistically analyzed (M:F=136/110). Mean duration study period was 13.6 (Std.dev.10.36) months (max 52 months). Patients were mainly men (55.3%), age >51 years (81.3%). The median of Hb level at baseline was 9.35 g/dL and after 12 months 10.4 g/dL respectively. After 12 months, most of patients had Hb range 10.0 g/dL to 11.0 g/dL. There were no statistically significant differences between Hb in groups of patients stratified according to the primary kidney disease and age, and between sex: mean level of Hb in M at the end of study was 10.27 g/dl and in F 10.58 g/dl (p=0.051). Baseline eGFR (Cocroft Gault) values were 16.31 (range form 4.1-62.6) vs. 16.71 (range from 4.9-43.8) mL/min after 12 months. The majority of patients had reported better exercise tolerance and sleep. 47.7% of patients have started after predialysis education with dialysis and in 2 patients preemptive transplantation was performed. The results of this multicenter observational study in Croatia suggest that the use of erythropoietin beta is effective and safe in correction of anemia in pre-dialysis CKD patients.
Keywords (croatian)
Keywords (english)
Languagecroatian
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleActa medica Croatica : Časopis Akademije medicinskih znanosti Hrvatske
Numberingvol. 70, no. Suplement 2, pp. 14-18
p-ISSN1330-0164
e-ISSN1848-8897
URN:NBNurn:nbn:hr:184:367067
Publication2017-04-06
Document URLhttp://hrcak.srce.hr/180117
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution 4.0 International (CC BY 4.0) icon
Created on2017-09-12 20:17:00